

Oral manifestations of aplastic anemia in children

Ester Sepúlveda, Ursula Brethauer, Jaime Rojas and Patricia Le Fort

J Am Dent Assoc 2006;137;474-478

The following resources related to this article are available online at jada.ada.org (this information is current as of July 4, 2009):

Updated information and services including high-resolution figures, can be found in the online version of this article at:

<http://jada.ada.org/cgi/content/full/137/4/474>

This article appears in the following **subject collections**:

Periodontics <http://jada.ada.org/cgi/collection/periodontics>

Information about obtaining **reprints** of this article or about permission to reproduce this article in whole or in part can be found at:

<http://www.ada.org/prof/resources/pubs/jada/permissions.asp>

Oral manifestations of aplastic anemia in children

Ester Sepúlveda, DDS; Ursula Brethauer, DDS; Jaime Rojas, MDS; Patricia Le Fort, MDS

Aplastic anemia (AA) is a rare blood dyscrasia in which peripheral blood pancytopenia results from reduced or absent blood cell production in the bone marrow, and normal hematopoietic tissue in the bone marrow has been replaced by fatty marrow.^{1,2} The estimated incidence of AA is two new cases per 1 million persons per year.³ The disease is rare in children and the peak age of occurrence is between 3 and 5 years.⁴ The disorder can be inherited, idiopathic or acquired; the causes include radiation therapy,⁵ intake of drugs and chemicals,⁶⁻⁹ viral infections,¹⁰⁻¹⁴ thymoma,¹⁵ pregnancy^{16,17} and paroxysmal nocturnal hemoglobinuria.¹⁸ However, the course, treatment and outcome are related more to the severity of the hematopoietic depression than to the cause.

BACKGROUND

Severe AA is defined by two of three criteria: neutrophil count less than 0.5×10^9 cells/liter (500 cells/cubic millimeter), platelet count less than 20×10^9 cells/L (20,000 cells/mm³) and reticulocyte count less than 1 percent. When the reticulocyte count is less than 0.2×10^9 cells/L (200 cells/mm³), the disease is characterized as very severe.¹⁹ Hematopoietic progenitors of mature red and white blood cells and megakaryocytes are virtually absent.²⁰

ABSTRACT



Background. Few studies concerning oral manifestations of aplastic anemia (AA) in children have been reported. The purpose of the authors' study was to describe oral lesions in children with AA.

Methods. The authors conducted a retrospective review using medical records of children diagnosed with AA who were treated at the Pediatric Service of the Regional Hospital of Concepción, Chile, between March 1996 and May 2001. They recorded episodes of oral mucosal lesions and assessed platelet and neutrophil counts at the time the oral lesions appeared.

Results. Twelve children (nine boys and three girls) were diagnosed with AA. Their age range was 3 to 12 years (median age, 7 years). Nine subjects were receiving immunosuppressive therapy, and three received only supportive care. The most common oral manifestation of the disease was hemorrhage, which developed most often in patients with platelet counts less than 25×10^9 cells/liter. The second and third most common oral manifestations were candidiasis and viral infection, respectively.

Conclusions. Children with AA frequently exhibit oral manifestations of the condition. Prevention, early diagnosis and proper treatment of oral complications are essential to diminish morbidity and avoid a possible fatal outcome.

Clinical Implications. Oral lesions can be the first manifestation of AA; consequently, dentists should be aware of these manifestations so that an early diagnosis of the disease can be made.

Key Words. Aplastic anemia; hemorrhage; candidiasis.

JADA 2006;137:474-8.

Dr. Sepúlveda is an associate professor, Department of Diagnosis and Oral Pathology, University of Concepción, Concepción, Chile.

Dr. Brethauer is an assistant professor, Department of Diagnosis and Oral Pathology, University of Concepción, Roosevelt 1550, Casilla 160-C, Concepción, Chile, e-mail "ubrethau@udec.cl". Address reprint requests to Dr. Brethauer.

Dr. Rojas is an oncohematologist, Pediatric Service, Regional Hospital, Concepción, Chile.

Dr. Le Fort is an oncohematologist, Pediatric Service, Regional Hospital, Concepción, Chile.

TABLE

Oral lesion episodes in 11 children with aplastic anemia during a five-year period.

ORAL LESION	NUMBER OF EPISODES
Hemorrhagic Episode	29
Candidiasis	10
Herpes Simplex	10
Herpangina	1
Varicella	1
Necrotizing Ulcerative Gingivitis	1
Pericoronitis	1
Gingival Hyperplasia	1
TOTAL	54

Bone marrow transplantation (BMT) and immunosuppressive therapy are the main therapeutic modalities used in pediatric patients. BMT is the treatment of choice for children with human leukocyte antigen-identical siblings, and immunosuppressive therapy is the treatment of choice for other children.²¹⁻²³ Immunosuppressive therapy can achieve a high response rate because of AA's immunitary nature in which bone marrow failure results from immunologically mediated, tissue-specific organ destruction.²⁴ However, this treatment increases the risk of morbidity in these patients.

Neutropenia, caused by the disorder itself and its treatment, leads to an increased susceptibility to infection, and thrombocytopenia leads to bruising and mucosal bleeding; both of these complications correspond to sepsis and hemorrhage, the main causes of death in these patients.²⁵⁻²⁷ The oral cavity is a common site of these complications, and early diagnosis and treatment of oral lesions are important to diminish the risks of morbidity and mortality in patients with AA.

Our literature search revealed few studies concerning oral manifestations of AA in children. Therefore, we conducted a study to describe oral mucosal lesions in children with AA who were treated at the Pediatric Service of the Regional Hospital of Concepción, Chile.

SUBJECTS AND METHODS

One of us (E.S.) conducted a retrospective review using medical records of children previously diag-




Figure 1. Ten-year-old patient with spontaneous gingival bleeding.

nosed with AA and treated at the Pediatric Service of the Regional Hospital of Concepción, Chile, between March 1996 and May 2001. She collected information about patient age, sex and medical treatment. In addition, she recorded episodes of oral mucosal lesions that developed during the hospitalization and assessed platelet and absolute neutrophil counts (ANCs) at the time the oral lesions appeared.

One calibrated oral surgeon (E.S.) determined the clinical diagnoses of all children with oral lesions. She used cultures to confirm the diagnosis of candidal lesions and an enzyme-linked immunosorbent assay test for herpes simplex virus type 1 and 2 to confirm the diagnosis of herpetic lesions.

RESULTS

Patient and treatment characteristics.

Twelve children had been diagnosed with AA and received medical care and follow-up at the Pediatric Service of the Regional Hospital of Concepción during the study period. Subjects' age range was 3 to 12 years, and their median age at the time of hospitalization was 7 years. Nine (75 percent) of the 12 children were male and three (25 percent) were female. Nine subjects received immunosuppressive therapy consisting of anti-lymphocyte globulin, cyclosporine and corticosteroids, and three children received supportive care only, because they died before beginning immunosuppressive therapy.

Assessment of oral mucosal lesions.



Figure 2. Thirteen-year-old patient with erythematous candidiasis of the tongue.



Figure 3. Eleven-year-old patient with intraoral herpes simplex type 1 of the gingiva and hard palate.

Overall, we documented a total of 54 episodes of oral lesions in 11 children (Table). The median number of episodes per patient was 5.36 (range, one to 26).

Hemorrhagic episodes. We observed 29 hemorrhagic episodes in seven patients. Twenty-seven of these were classified as intraoral

petechiae (n = 8), ecchymoses (n = 8), hematomas (n = 7) and spontaneous bleeding of the gingiva (n = 4) (Figure 1). In addition, we observed two hemorrhages after tooth extractions. The first clinical manifestation of AA before diagnosis in three children were bleeding episodes in the oral cavity. Eleven hemorrhagic episodes occurred in patients with platelet counts less than 10×10^9 cells/L (10,000 cells/mm³), 16 in patients with platelet counts greater than 10×10^9 cells/L but less than 25×10^9 cells/L (25,000 cells/mm³) and two in patients with platelet counts greater than 25×10^9 cells/L (normal platelet counts are 220 to 250×10^9 cells/L).

Candidiasis. We documented candidiasis episodes in five patients. We observed intraoral erythematous candidiasis (n = 6) (Figure 2) and commissural fungal cheilitis (n = 4). Five episodes occurred when the ANC was greater than 1×10^9 cells/L (1,000 cells/mm³) and five occurred when the ANC was less than 1×10^9 cells/L.

A total of 12 viral lesions developed in nine patients, including labial (n = 5) and intraoral (n = 5) herpes simplex (Figure 3) herpangina (n = 1) and varicella-zoster (n = 1). In 10 cases of viral infection, the ANC was less than 1×10^9 cells/L, and in two cases, it was greater than 1×10^9 cells/L.

DISCUSSION

Similar to the results of a previous study conducted in adults with AA,²⁸ we found that hemorrhagic episodes were the most common oral manifestation in patients. These results differ from those found in immunosuppressed children with other diseases, such as leukemia, lymphomas and other malignancies.²⁹⁻³¹ The most frequent oral lesions observed in those patients were nonspecific ulcers, mucositis and candidiasis.²⁹⁻³¹ In addition, Leggot and colleagues³² found that candidiasis was the most common oral disease affecting patients with immunodeficiencies such as HIV infection.

As stated above, there are two main approaches to treating patients with AA: BMT and immunosuppressive therapy.^{22,33,34} No patients in our study group received BMT treatment; all patients received pharmacological therapy, resulting in a homogeneous population. Although immunosuppressive therapy has been shown to be effective in improving bone marrow function in most patients with AA, it commonly induces defects in host defense (pancytopenia)

that contribute to the underlying disease.^{35,36}

We must point out that 11 (92 percent) of 12 children in our study experienced at least one episode of oral infection (fungal, viral or bacterial) during the study period. The mouth is a port of entry for early infections in these patients that can complicate general conditions and even be life-threatening.^{37,38} In fact, three patients in our study died of bacterial sepsis before beginning immunosuppressive therapy.

Although fungal and viral infections usually are associated with absolute lymphocyte count, we did not assess this in our study. Further investigations are needed to determine the relationship between absolute lymphocyte count and infection in patients with AA.

The first clinical manifestation of AA before diagnosis was an oral hemorrhagic episode in three (25 percent) of 12 children. One of these cases has been reported elsewhere.³⁹ This illustrates the importance of conducting a rigorous clinical evaluation of a patient with unexplained or persistent bleeding in the oral cavity.

Eighteen (62 percent) of 29 hemorrhagic episodes observed in our study occurred in subjects with platelet counts greater than 10×10^9 cells/L, while only 11 (38 percent) occurred in subjects with platelet counts less than 10×10^9 cells/L. This might have resulted because the latter group received prophylactic platelet transfusions and a soft diet to avoid hemorrhage. Children with platelet counts of more than 10×10^9 cells/L did not receive prophylactic platelet support or a soft diet.

Gingival hyperplasia was rare (only one case), although most of the children (nine [75 percent] of 12) were being treated with cyclosporine, which is known to induce this type of pathology.^{40,41} A possible explanation for this is that at the time of the oral examination during the hospital stay, some patients had been receiving cyclosporine treatment for only a short period.

One limitation of this study is the small sample size, resulting from the low incidence of AA in children.

CONCLUSION

Children with AA frequently have oral lesions associated with their systemic condition and therapy. Hemorrhagic episodes were the most commonly observed oral manifestation of the disease in this study, especially in patients whose platelet counts were less than 25×10^9 cells/L.

Further investigations are needed to assess the prevalence of these oral manifestations in children with AA, as well as to evaluate their severity and the possible related fatal outcome. ■

This study was supported by grant 98.103.008-1.0 from the Research Department, University of Concepción, Chile.

1. Valdez IH, Patton LL. Aplastic anemia: current concepts and dental management. *Spec Care Dentist* 1990;10(6):185-9.
2. Geissler K. Pathophysiology and treatment of aplastic anemia. *Wien Klin Wochenschr* 2003;115:444-50.
3. Young NS. Acquired aplastic anemia. *JAMA* 1999;282:271-8.
4. McWhorter AG, Hill SD. Conservative management for a patient with aplastic anemia without use of blood products: case report. *Pediatr Dent* 1991;13:224-6.
5. Muir KR, Chilvers CE, Harriss C, et al. The role of occupational and environmental exposures in the aetiology of acquired severe aplastic anaemia: a case control investigation. *Br J Haematol* 2003;123:906-14.
6. Vincent PC. Drug-induced aplastic anaemia and agranulocytosis: incidence and mechanisms. *Drugs* 1986;31(1):52-63.
7. West BC, DeVault GA Jr, Clement JC, Williams DM. Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine. *Rev Infect Dis* 1988;10:1048-51.
8. Yanez Rubal JC, Estevez Rodriguez J, Crespo-Lopez MC, Martin-Herranz I. Carbamazepine-induced aplastic anaemia: a case report [in Spanish]. *Rev Neurol* 2002;35:647-9.
9. Parent-Massin D, Thouvenot D, Rio B, Riche C. Lindane haematotoxicity confirmed by in vitro tests on human and rat progenitors. *Hum Exp Toxicol* 1994;13(2):103-6.
10. Kurtzman G, Young N. Viruses and bone marrow failure. *Baillieres Clin Haematol* 1989;2(1):51-67.
11. Liang DC, Lin KH, Lin DT, Yang CP, Hung KL, Lin KS. Post-hepatic aplastic anaemia in children in Taiwan, a hepatitis prevalent area. *Br J Haematol* 1990;74:487-91.
12. Brown KE, Tisdale J, Barrett AJ, Dunbar CE, Young NS. Hepatitis-associated aplastic anemia. *N Engl J Med* 1997;336:1059-64.
13. Maciejewski JP, Bruening EE, Donahue RE, Mocarski ES, Young NS, St Jeor SC. Infection of hematopoietic progenitor cells by human cytomegalovirus. *Blood* 1992;80(1):170-8.
14. Knox KK, Carrigan DR. In vitro suppression of bone marrow progenitor cell differentiation by human herpesvirus 6 infection. *J Infect Dis* 1992;165:925-9.
15. Park CY, Kim HJ, Kim YJ, et al. Very severe aplastic anemia appearing after thymectomy. *Korean J Intern Med* 2003;18(1):61-3.
16. Choudhry VP, Gupta S, Gupta M, Kashyap R, Saxena R. Pregnancy associated aplastic anemia: a series of 10 cases with review of literature. *Hematology* 2002;7:233-8.
17. Deka D, Malhotra N, Sinha A, Banerjee N, Kashyap R, Roy KK. Pregnancy associated aplastic anemia: maternal and fetal outcome. *J Obstet Gynaecol Res* 2003;29(2):67-72.
18. Schrezenmeier H, Hertenstein B, Wagner B, Raghavachar A, Heimpel H. A pathogenetic link between aplastic anemia and paroxysmal nocturnal hemoglobinuria is suggested by a high frequency of aplastic anemia patients with a deficiency of phosphatidylinositol glycan anchored proteins (erratum published in *Exp Hematol* 1995;23[2]:181). *Exp Hematol* 1995;23(1):81-7.
19. Young NS. Acquired aplastic anemia. *Ann Intern Med* 2002;136:534-46.
20. Scopes J, Bagnara M, Gordon-Smith EC, Ball SE, Gibson FM. Haematopoietic progenitor cells are reduced in aplastic anaemia. *Br J Haematol* 1994;86:427-30.
21. Fouladi M, Herman R, Rolland-Grinton M, et al. Improved survival in severe acquired aplastic anemia in childhood. *Bone Marrow Transplant* 2000;26:1149-56.
22. Kojima S, Horibe K, Inaba J, et al. Long-term outcome of acquired aplastic anemia in children: comparison between immunosuppressive therapy and bone marrow transplantation. *Br J Haematol* 2000;111:321-8.
23. Locasciulli A. Acquired aplastic anemia in children: incidence, prognosis and treatment options. *Paediatr Drugs* 2002;4:761-6.
24. Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. *N Engl J Med* 1997;336:1365-72.
25. Kim I, Yoon SS, Park S, Kim BK, Kim NK. The treatment of severe aplastic anemia: outcomes of bone marrow transplantation and

immunosuppressive therapy in a single institution of Korea. *J Korean Med Sci* 2003;18:365-71.

26. Torres HA, Bodey GP, Rolston KV, Kantarjian HM, Raad II, Kontoyiannis DP. Infections in patients with aplastic anemia: experience at a tertiary care cancer center. *Cancer* 2003;98(1):86-93.

27. Feng YH, Yen CJ, Huang WT, Su WC, Chen TY, Tsao CJ. Clinical response of antilymphocyte globulin-based treatment in patients in Taiwan with aplastic anemia: positive hepatitis C antibody may represent a response predictor. *Int J Hematol* 2004;79(2):133-7.

28. Brennan MT, Sankar V, Baccaglini L, et al. Oral manifestations in patients with aplastic anemia. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2001;92:503-8.

29. Fayle SA, Curzon ME. Oral complications in pediatric oncology patients. *Pediatr Dent* 1991;13:289-95.

30. Kamp AA. Neoplastic diseases in a pediatric population: a survey of the incidence of oral complications. *Pediatr Dent* 1988;10(1):25-9.

31. Sepúlveda E, Brethauer U, Morales R, Jiménez M. Oral manifestations in pediatric patients with oncologic pathology. *Med Oral* 2000;5(3):193-7.

32. Leggot PJ, Robertson PB, Greenspan D, Wara DW, Greenspan JS. Oral manifestation of primary and acquired immunodeficiency diseases in children. *Pediatr Dent* 1987;9(2):98-104.

33. Ahn MJ, Choi JH, Lee YY, et al. Outcome of adult severe or very severe aplastic anemia treated with immunosuppressive therapy compared with bone marrow transplantation: multicenter trial. *Int J Hematol* 2003;78(2):133-8.

34. Abdelkefi A, Ben Othman T, Ladeb S, Torjman L, Hsairi M, Ben Abdeladhim A. Bone marrow transplantation for patients with acquired severe aplastic anemia using cyclophosphamide and antithymocyte globulin: the experience from a single center. *Hematol J* 2003;4:208-13.

35. Kojima S, Nakao S, Tomonaga M, et al. Consensus conference on the treatment of aplastic anemia. *Int J Hematol* 2000;72(1):118-23.

36. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. *Blood* 2003;101:1236-42.

37. Connolly SF, Lockhart PB, Sonis ST. Severe oral hemorrhage and sepsis following bone marrow transplant failure. *Oral Surg Oral Med Oral Pathol* 1983;56:483-6.

38. Heimdahl A, Mattsson T, Dahllöf G, Lönnquist B, Ringden O. The oral cavity as a port of entry for early infections in patients treated with bone marrow transplantation. *Oral Surg Oral Med Oral Pathol* 1989;68:711-6.

39. Sepúlveda E, Rojas Castro J. Signs of medullar aplasia in the oral cavity: report of case. *ASDC J Dent Child* 2001;68(1):32, 70-2.

40. Seymour RA, Jacobs DJ. Cyclosporin and the gingival tissues. *J Clin Periodontol* 1992;19(1):1-11.

41. Tyldesley WR, Rotter E. Gingival hyperplasia induced by cyclosporine-A. *Br Dent J* 1984;157:305-9.